Olivier Roques, CEO of BENEO In a strategic effort to enhance early-life nutrition, BENEO and WACKER have partnered to develop and globally launch 2’-Fucosyllactose (2’-FL), the most abundant and well-researched human milk oligosaccharide (HMO). This collaboration combines BENEO’s extensive expertise in prebiotics with WACKER’s advanced fermentation technology, highlighting their shared[Read More…]
Tag: HMO
Preclinical study shows combination of chicory-derived prebiotics and HMO for toddler gut health
The science-driven, ingredient-specific research, conducted in collaboration with leading academic partner ETH Zurich, focused on microbial composition and metabolic effects in early nutrition A new preclinical study, conducted by Pudenz et al., i demonstrates that combining chicory-derived inulin-type fructans with the human milk oligosaccharide (HMO) 2’-fucosyllactose (2’-FL) leads to additive, and even synergistic,[Read More…]
BENEO and WACKER launch human milk oligosaccharides
The product launch is the first result of a strategic and global partnership that the companies entered into to collaborate on enhancing early-life nutrition BENEO, a leading manufacturer of functional ingredients for food, feed and pharma, and WACKER, a European expert in biotechnology solutions for the food and pharma industry,[Read More…]
Mengniu driving development of innovative HMO nutritional ingredients
Mengniu emerge as a pioneer in developing nutritional ingredients, particularly through groundbreaking advancements in HMO technology In August 2024, Synaura Biotechnology a subsidiary of China Mengniu Dairy Company Limited, received GRAS certification from the U.S. Food and Drug Administration (FDA) for its 2′-FL (2′-Fucosyllactose), making it the first and only[Read More…]
Illuma unveils next-generation HMO innovations
Illuma has swiftly launched many remarkable HMO products in China Recently at Nestlé’s headquarters in Vevey, Switzerland, illuma, a global super premium brand of maternal and infant nutrition under Nestlé, began its “Human Milk Oligosaccharides (HMO) Research Traceability Journey”. With a focus on the most recent advancements in the field of human milk research, particularly[Read More…]
Wyeth launches China’s first infant formula with two types of HMOs
This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months Filling a gap in the local HMO market, the recently released illuma HMO Liquid Formula is the first in China to contain two essential HMOs, 2′-Fucosyllactose (2′-FL) and Lacto-N-neotetraose (LNnT). This clinically proven product offers[Read More…]
dsm firmenich announces approval of HMO ingredients for infant nutrition in Australia and New Zealand
dsm-firmenich is the first HMO manufacturer to apply and obtain approval for the four HMOs in this region dsm-firmenich, a leading innovator in health, nutrition and beauty, announced that it has gained approval for an additional four human milk oligosaccharide (HMO) ingredients for use as nutritive substances in infant formula products in[Read More…]
New Illuma HMO growing-up infant formula available in China
Wyeth becomes the first foreign company that sell HMO infant formula added with two HMOs in China Wyeth Nutrition announced that its first illuma HMO growing-up infant formula added with two human milk oligosaccharides (HMOs) is now available throughout China, which makes Wyeth Nutrition the first multinational company that sells the HMO[Read More…]
Wyeth becomes first MNC to launch HMO growing-up infant formula in China
Designed for babies above 3 years old, this product is manufactured at the company’s GMP-level factory in Suzhou Wyeth Nutrition announced the launch of its first illuma HMO Growing-up infant formula added with two human milk oligosaccharides (HMOs) in China. Designed for babies above 3 years old, this product is manufactured at[Read More…]
dsm-firmenich achieves regulatory clearance in China for HMO ingredients
The two HMOs that received approval in China include GlyCare 2’-fucosyllactose (2’-FL), the most prevalent HMO in human breast milk, and GlyCare lacto-N-neotetraose (LNnT) dsm-firmenich, the leading innovator in health, nutrition and beauty, announced that two of its human milk oligosaccharide (HMO) ingredients have been approved as fortifiers for infant[Read More…]
